NCT03004768View on ClinicalTrials.gov

Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 26, 2017

Primary Completion Date

February 27, 2017

Study Completion Date

February 27, 2017

Conditions
Psoriasis
Interventions
DRUG

BMS-986165

Oral solution dose of 24 mg \[14C\] BMS-986165 containing approximately 100 micro Ci of TRA

Trial Locations (1)

53704

Covance Madison Clinical Research Unit, Madison

Sponsors

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT03004768 - Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants | Biotech Hunter | Biotech Hunter